HomeHong KongORI Capital Raises $260M for Second Life Sciences Fund

ORI Capital Raises $260M for Second Life Sciences Fund

ori capital

ORI Capital, a Hong Kong- and Natick, MA-based quantamental venture capital firm, closed its second fund, ORI Fund II, with total commitments of $260M.

Backers included institutional, strategic and high net worth investors globally.

Founded in 2015, and led by veteran investor, Simone Song, ORI Capital has identified several themes of fundamental innovation as well as structural shifts that will drive significant growth in the coming decades. These themes include next generation small molecules such as RNA targeting small molecules, protein degradation and stabilization, the programmable nuclear acid therapies such as DNA and RNA therapies, immuno-oncology cell therapy, and synthetic biology. ORI Healthcare Fund II will actively invest in innovative early-stage biotech companies globally, across the areas of diagnostics, drug delivery, and therapeutics focused on areas of significant unmet medical need with the highest mortality rates such as cancer, metabolic disorders and neurodegenerative diseases.

The firm adopts a quantamental strategy in biotech venture investment combing data analysis with fundamental research. Its proprietary big data and artificial intelligence (AI) research system, ORIZON, provides daily updates on 31,000+ healthcare companies around the world, follows 62,000+ key opinion leaders, and tracks the investment activities of 5,000+ fund managers.

Notable exits include:

  • CG Oncology’s (NASDAQ:CGON) recent IPO on the NASDAQ which raised an double upsized offering of $380 million,
  • Kymab which was acquired by Sanofi in January 2021 for $1.1 billion upfront,
  • Semma Therapeutics which was acquired by Vertex in 2019 for $950 million in cash, as well as
  • Orchard Therapeutics (NASDAQ:ORTX) and TriSalus Life Sciences (NASDAQ: TLSI) which both listed on the NASDAQ.